Baxter International Stock (BAX)

XNYS Alert Compare

Health Care · Fundamental analysis

· How we analyze

Metrics from daily candles, as of Nov 20, 2026 · Extended universe

Figures in the price bar from TradingView (mostly trailing 12 months) · our fundamental analysis uses the fiscal year

Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Academy: 200-day line · RSI

About the company

Baxter International is a US medical technology company. It makes IV solutions and infusion pumps, hospital beds, monitoring devices and surgical products. The kidney dialysis business was sold as Vantive. Customers are mainly hospitals worldwide. As of Oct 11, 2026

Fact sheet (from the annual report) Medical instruments · Deerfield, USA

Baxter offers sterile IV solutions, infusion systems, parenteral nutrition therapies, inhaled anesthetics and generic injectable drugs. It also offers products for stopping bleeding in surgery, surgical equipment, connected bed systems, patient monitoring and respiratory devices. Its reportable segments are Medical Products & Therapies, Healthcare Systems & Technologies and Pharmaceuticals. The products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors’ offices, dialysis centers and in patients’ homes under medical supervision. In January 2025 Baxter completed the sale of its Kidney Care business to Carlyle, and in September 2023 that of its BioPharma Solutions business. Sales run through its own field sales force, independent distributors and wholesalers.

Automatically summarized from SEC annual report (10-K, filed Feb 12, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026

Price performance at a glance

Last 30 trading days
  • Today −0.0%
  • 7 days −1.7%
  • 30 days +2.8%
  • 1 year +45.7%
Day range (last trading day)
−2.1%Price at 43% of the range+2.8%
52-week range
−38.0%Price at 68% of the range+18.2%
Distance from the all-time high
−73.3%

Our own calculation from the exchange’s daily candles, as of Nov 20, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Fundamentals · Analysis method

Growth, margin, balance sheet, cash flow and dividend compared with the sector – with traffic lights and quality checks in the fundamental analysis. To the fundamental analysis

Fundamental analysis

Baxter International · Sector Health Care · amounts in USD

Source: SEC filings, As of Feb 12, 2026.

For you first Dividend

The dividend per share was cut in fiscal year 2025 compared with the year before; free cash flow per share covers it 1.2x.

Years without a cut
0
cut in fiscal year 2025
Growth per year (5 yrs)
−11.4%
dividend per share, average per year
Coverage by free cash flow
1.2x
covered from 1.0x

For you first Valuation

There is no comparison for the P/E: the last fiscal year ended with a loss.

With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free

For you first Growth

How strongly revenue and earnings per share have grown over the years.

Check “Growth”
1 of 7
criteria with data met
Revenue per year (5 y)
−0.7%

For you first Quality

How much of revenue remains and whether profit arrives as cash.

Check “Quality”
2 of 8
criteria with data met
Net margin
−8.5%
Return on equity
−15.6%

For you first Trading

The overview of this stock shows the trend by timeframe.

Quality checks

Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.

Fiscal year to Dec 31, 2025

Quality 2 of 8 met

  • not met: Gross margin above 40% 30.1%
  • not met: Operating margin above 15% −2.7%
  • not met: Net margin above 10% −8.5%
  • not met: Return on equity above 15% −15.6%
  • not met: Free cash flow margin above 10% 3.0%
  • not met: Profit in each of the last 5 fiscal years 2 of 5
  • met: Free cash flow positive in each of the last 3 fiscal years 3 of 3
  • met: Equity ratio above 30% 30.6%
Gross margin

30.1% Fiscal year 2025

Rank 22 of 100: higher than 22% of 370 peers (All). weak.

Rank 11 of 100: higher than 11% of 49 peers (Sector). weak.

Median Health Care: 61.8%

Share of revenue left after the direct cost of the products sold.

Operating margin

−2.7% Fiscal year 2025

Rank 13 of 100: higher than 13% of 470 peers (All). weak.

Rank 10 of 100: higher than 10% of 54 peers (Sector). weak.

Median Health Care: 17.0%

Operating income divided by revenue: what the core business earns before interest and taxes.

Net margin

−8.5% Fiscal year 2025

Rank 8 of 100: higher than 8% of 584 peers (All). weak.

Rank 7 of 100: higher than 7% of 63 peers (Sector). weak.

Median Health Care: 12.9%

Profit after all costs, interest and taxes divided by revenue.

Return on equity

−15.6% Fiscal year 2025

Rank 7 of 100: higher than 7% of 544 peers (All). weak.

Rank 8 of 100: higher than 8% of 54 peers (Sector). weak.

Median Health Care: 12.8%

Net income divided by equity at fiscal year end.

Return on assets

−4.8% Fiscal year 2025 (total assets at year end)

Rank 8 of 100: higher than 8% of 594 peers (All). weak.

Rank 9 of 100: higher than 9% of 63 peers (Sector). weak.

Median Health Care: 6.6%

Net income divided by total assets at fiscal year end.

Equity ratio

30.6% Fiscal year 2025

Rank 40 of 100: higher than 40% of 595 peers (All). medium.

Rank 31 of 100: higher than 31% of 63 peers (Sector). weak.

Median Health Care: 44.2%

Equity as a share of total assets. Usually low for banks.

Free cash flow margin

3.0% Fiscal year 2025

Rank 23 of 100: higher than 23% of 465 peers (All). weak.

Rank 20 of 100: higher than 20% of 61 peers (Sector). weak.

Median Health Care: 14.5%

Free cash flow divided by revenue.

Free cash flow

332.0M USD Fiscal year 2025

Operating cash flow minus capital expenditure on property and equipment.

Growth 1 of 7 met

  • not met: Over 3 years, revenue grew by more than 5% per year −9.4%
  • not met: Over 5 years, revenue grew by more than 5% per year −0.7%
  • not met: Over 10 years, revenue grew by more than 5% per year +1.2%
  • not met: Over 3 years, EPS grew by more than 5% per year no earnings per share in the last fiscal year
  • not met: Over 5 years, EPS grew by more than 5% per year no earnings per share in the last fiscal year
  • not met: Revenue rose in at least 4 of the last 5 fiscal years 3 of 5
  • met: Revenue rose in the last fiscal year +5.7%
Revenue growth 3 years

−9.4% per year

Rank 5 of 100: higher than 5% of 578 peers (All). weak.

Rank 6 of 100: higher than 6% of 62 peers (Sector). weak.

Median Health Care: +5.1%

Average growth per year over 3 fiscal years.

Revenue growth 5 years

−0.7% per year

Rank 6 of 100: higher than 6% of 549 peers (All). weak.

Rank 4 of 100: higher than 4% of 60 peers (Sector). weak.

Median Health Care: +7.8%

Average growth per year over 5 fiscal years.

Revenue growth 10 years

+1.2% per year

Rank 12 of 100: higher than 12% of 412 peers (All). weak.

Rank 5 of 100: higher than 5% of 50 peers (Sector). weak.

Median Health Care: +9.3%

Average growth per year over 10 fiscal years.

Dividend 4 of 7 met

  • met: Pays a dividend 0.52 USD
  • not met: Payout ratio at most 60% of earnings despite a loss
  • met: Dividend paid in each of the last 5 fiscal years 5 of 5
  • not met: Dividend per share never lowered in the last 5 fiscal years Dividend per share as filed with the SEC, including special dividends; a one-off higher prior year does not count as a cut. 2 times
  • not met: Dividend per share higher than 5 years ago −11.4%
  • met: Free cash flow per share covers the dividend 1.2x
  • met: Dividends paid over the last 5 years covered by free cash flow 67% of free cash flow
Dividend growth 5 years

−11.4% per year

Rank 1 of 100: higher than 1% of 321 peers (All). weak.

Rank 2 of 100: higher than 2% of 31 peers (Sector). weak.

Median Health Care: +6.6%

Growth of the dividend per share per year.

Free cash flow coverage

1.2x Fiscal year 2025

Free cash flow per share divided by dividend per share. From 1x the dividend is covered.

Financial strength 4 of 6 met

  • not met: Piotroski F-Score at least 7 of 9 5 of 9
  • not met: Long-term debt no higher than equity 1.55
  • met: Current assets cover current liabilities 2.31
  • met: Positive equity 6.1B USD
  • met: In 5 years, share count up by at most 5% −0.8%
  • met: Free cash flow positive in the last fiscal year 332.0M USD
Piotroski F-Score

5 of 9 Fiscal year 2025

Rank 22 of 100: higher than 22% of 310 peers (All). weak.

Rank 17 of 100: higher than 17% of 47 peers (Sector). weak.

Median Health Care: 6.0 of 9

Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.

Debt / equity

1.55 at fiscal year end

Rank 18 of 100: lower than 18% of 486 peers (All). weak.

Rank 11 of 100: lower than 11% of 50 peers (Sector). weak.

Median Health Care: 0.66

Long-term financial debt divided by equity.

Liquidity (current ratio)

2.31 at fiscal year end

Rank 79 of 100: higher than 79% of 513 peers (All). strong.

Rank 75 of 100: higher than 75% of 63 peers (Sector). strong.

Median Health Care: 1.58

Current assets divided by current liabilities.

Change in share count

−0.8% in 5 years

Rank 42 of 100: lower than 42% of 507 peers (All). medium.

Rank 33 of 100: lower than 33% of 59 peers (Sector). medium.

Median Health Care: −4.3%

Change in diluted share count. Negative = share buybacks, positive = new shares.

The 9 criteria of the Piotroski F-Score
  • not met: Profit in the last fiscal year (positive return on assets)
  • met: Positive operating cash flow
  • not met: Return on assets higher than the prior year
  • met: Operating cash flow higher than net income
  • met: Long-term debt relative to total assets fell
  • met: Liquidity (current assets / current liabilities) rose
  • not met: No additional shares (diluted share count did not rise)
  • not met: Gross margin higher than the prior year
  • met: Revenue relative to total assets higher than the prior year

Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.

Price-based criteria (P/E, dividend yield) are shown to signed-in users.

Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.

In short

  • Light red: Revenue shrank over 5 years (−0.7% per year).
  • Light red: Loss in the last fiscal year.
  • Light red: Debt much higher than usual in the sector.
  • Light red: Profit in 7 of 10 fiscal years.
  • Light red: Dividend higher than earnings.

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 10.2B USD · Net income 5.0B USD · Net margin 48.9%
  2. Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 10.6B USD · Net income 717.0M USD · Net margin 6.8%
  3. Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 11.1B USD · Net income 1.6B USD · Net margin 14.6%
  4. Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 11.4B USD · Net income 1.0B USD · Net margin 8.8%
  5. Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 11.7B USD · Net income 1.1B USD · Net margin 9.4%
  6. Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 12.8B USD · Net income 1.3B USD · Net margin 10.0%
  7. Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 15.1B USD · Net income −2.4B USD · Net margin −16.1%
  8. Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 14.8B USD · Net income 2.7B USD · Net margin 17.9%
  9. Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 10.6B USD · Net income −649.0M USD · Net margin −6.1%
  10. Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 11.2B USD · Net income −957.0M USD · Net margin −8.5%

Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 11.2B USD · Net income −957.0M USD · Net margin −8.5%

How has it gone since the last annual report?

Trailing 12 months and quarters

Revenue in the quarter to Sep 2026 +5.0% vs. the same quarter a year earlier; grown for at least 13 quarters in a row.

Revenue 12 months vs. prior 12
+5.3%
12 months: 11.6B USD · Fiscal year 2025: +5.7%
Net margin 12 months
−6.2%
Fiscal year 2025: −8.5%
Free cash flow margin 12 months
–
Cash flow or capital expenditure not reported
More depth

Calculation of the 12 months to Sep 30, 2026

  • Revenue: fiscal year to Dec 31, 2025 11.2B USD + year to date to Sep 30, 2026 8.6B USD − same period a year earlier to Sep 30, 2025 8.3B USD = 11.6B USD
  • Net income: fiscal year to Dec 31, 2025 −957.0M USD + year to date to Sep 30, 2026 405.0M USD − same period a year earlier to Sep 30, 2025 171.0M USD = −723.0M USD
  • Operating cash flow: fiscal year to Dec 31, 2025 845.0M USD + year to date to Sep 30, 2026 1.1B USD − same period a year earlier to Sep 30, 2025 261.0M USD = 1.6B USD
By quarter (latest first, amounts in USD)
QuarterRevenuevs. year agoNet incomeMargin
Jul–Sep 263.0B+5.0%294.0M9.9%
Apr–Jun 263.0B+5.3%126.0M4.3%
Jan–Mar 262.7B+2.9%−15.0M−0.6%
Oct–Dec 25*3.0B+8.0%−1.1B−37.9%
Jul–Sep 252.8B+5.0%−46.0M−1.6%
Apr–Jun 25²2.8B+4.3%91.0M3.2%
Jan–Mar 25²2.6B+5.4%126.0M4.8%
Oct–Dec 24²2.8B+0.9%−512.0M−18.6%

Trailing 12 months = last fiscal year + the period since the start of the current fiscal year − the same period a year earlier, each from the first filing. P/E, PEG and the quality checks still use the last fiscal year.

Each quarter is compared with the same quarter a year earlier.

* derived: fiscal year minus the first 9 months.

² Year-ago quarter restated after a spin-off or divestiture – compared with the restated figure from the same report.

As of: 12 months to Sep 30, 2026, filed on Oct 29, 2026 · Source: SEC filings (10-Q, 10-K)

Does the profit arrive as cash?

Earnings quality

There was no profit in fiscal year 2025; operating income does not cover interest.

Cash flow ÷ profit
–
no profit in fiscal year 2025
Interest coverage
negative
operating income negative · 3 years: 0.1x
Tax rate
–
no profit before tax
More depth

Calculation for fiscal year 2025

  • Operating cash flow 845.0M USD ÷ Net income −957.0M USD = no ratio (no profit)
  • Operating income −308.0M USD ÷ Interest expense 290.0M USD = negative
  • Taxes 395.0M USD ÷ profit before tax −505.0M USD = no rate (no profit before tax)
By fiscal year
FYCash flow ÷ profitInterest coverageTax rate
2025–negative–
2024–0.0x–
20230.65x0.8x–
2022–negative–
20211.72x8.3x12.3%

How it is rated: cash flow ÷ profit from 1.0 “backed by cash”, below 0.8 “profit well above the cash coming in”; interest coverage from 5 “well covered”, below 2 “thinly covered”. The tax rate is only shown.

Cash flow ÷ profit uses group profit incl. minority interests, because cash flow also covers the whole group. Profit before tax as reported to the SEC, otherwise approximated. “3 years” = sums of the last three fiscal years – only if every year is reported and the figures have the same origin; for cash flow only with a profit in every year.

As of fiscal year 2025 · Source: SEC filings

How even were the last years?

Consistency

In 10 fiscal years 3 loss years and 2 years with lower revenue.

Loss years
3 of 10
net income below zero
Years with lower revenue
2 of 10
revenue below the prior year
Net margin range
65.0 percentage points
from −16.1% to 48.9%
Net margin by fiscal year · ▾ revenue below the prior year
More depth
By fiscal year
FYRevenue vs. prior yearNet margin
2025+5.7%−8.5%
2024−28.2%−6.1%
2023−2.0%17.9%
2022+18.2%−16.1%
2021+9.5%10.0%
2020+2.7%9.4%
2019+2.1%8.8%
2018+5.4%14.6%
2017+3.9%6.8%
2016+2.0%48.9%

Loss year: net income below zero. Lower revenue: revenue below the prior year. Range: highest minus lowest net margin; margins beyond ±200% do not count. No score – only the reported figures.

As of fiscal years 2016–2025 · Source: SEC filings

Figures over time

Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.

Money flow in fiscal year 2025

Of 100 USD of revenue, 30.1 USD gross profit remained.

Operating loss: −2.7% of revenue

Money flow as a table
Fiscal year 2025, amounts in USD, share of revenue
ItemAmountof revenue
Revenue11.2B USD100.0%
Gross profit3.4B USD30.1%
Cost of revenue7.9B USD69.9%
Operating expenses3.7B USD32.8%

Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.

Margins

The operating margin fell in 5 years from 13.8% to −2.7%.

Gross marginOperating marginNet margin
  1. Fiscal year 2016: Gross margin 40.4% · Operating margin 7.1% · Net margin 48.9%
  2. Fiscal year 2017: Gross margin 42.2% · Operating margin 11.9% · Net margin 6.8%
  3. Fiscal year 2018: Gross margin 43.0% · Operating margin 14.4% · Net margin 14.6%
  4. Fiscal year 2019: Gross margin 41.9% · Operating margin 15.6% · Net margin 8.8%
  5. Fiscal year 2020: Gross margin 39.3% · Operating margin 13.8% · Net margin 9.4%
  6. Fiscal year 2021: Gross margin 39.9% · Operating margin 13.4% · Net margin 10.0%
  7. Fiscal year 2022: Gross margin 35.7% · Operating margin −12.9% · Net margin −16.1%
  8. Fiscal year 2023: Gross margin 33.6% · Operating margin 2.6% · Net margin 17.9%
  9. Fiscal year 2024: Gross margin 37.5% · Operating margin 0.1% · Net margin −6.1%
  10. Fiscal year 2025: Gross margin 30.1% · Operating margin −2.7% · Net margin −8.5%

Returns

Return on equity fell in 5 years from 12.7% to −15.6%.

Return on equityReturn on assets
  1. Fiscal year 2016: Return on equity 59.9% · Return on assets 31.9%
  2. Fiscal year 2017: Return on equity 7.9% · Return on assets 4.2%
  3. Fiscal year 2018: Return on equity 20.8% · Return on assets 10.4%
  4. Fiscal year 2019: Return on equity 12.7% · Return on assets 5.5%
  5. Fiscal year 2020: Return on equity 12.7% · Return on assets 5.5%
  6. Fiscal year 2021: Return on equity 14.1% · Return on assets 3.8%
  7. Fiscal year 2022: Return on equity −41.7% · Return on assets −8.6%
  8. Fiscal year 2023: Return on equity 31.6% · Return on assets 9.4%
  9. Fiscal year 2024: Return on equity −9.3% · Return on assets −2.5%
  10. Fiscal year 2025: Return on equity −15.6% · Return on assets −4.8%

Equity and long-term debt

The equity ratio fell in 5 years from 43.4% to 30.6%.

EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases.
  1. Fiscal year 2016: Equity 8.3B USD · Long-term debt 2.8B USD
  2. Fiscal year 2017: Equity 9.1B USD · Long-term debt 3.5B USD
  3. Fiscal year 2018: Equity 7.8B USD · Long-term debt 3.5B USD
  4. Fiscal year 2019: Equity 7.9B USD · Long-term debt 5.1B USD
  5. Fiscal year 2020: Equity 8.7B USD · Long-term debt 6.2B USD
  6. Fiscal year 2021: Equity 9.1B USD · Long-term debt 17.7B USD
  7. Fiscal year 2022: Equity 5.8B USD · Long-term debt 16.6B USD
  8. Fiscal year 2023: Equity 8.4B USD · Long-term debt 13.8B USD
  9. Fiscal year 2024: Equity 7.0B USD · Long-term debt 13.1B USD
  10. Fiscal year 2025: Equity 6.1B USD · Long-term debt 9.5B USD

Liquidity (current ratio)

The current ratio fell in 5 years from 2.52 to 2.31.

Current ratio
  1. Fiscal year 2016: Current ratio 2.40
  2. Fiscal year 2017: Current ratio 2.57
  3. Fiscal year 2018: Current ratio 2.09
  4. Fiscal year 2019: Current ratio 2.32
  5. Fiscal year 2020: Current ratio 2.52
  6. Fiscal year 2021: Current ratio 2.09
  7. Fiscal year 2022: Current ratio 1.69
  8. Fiscal year 2023: Current ratio 1.48
  9. Fiscal year 2024: Current ratio 1.36
  10. Fiscal year 2025: Current ratio 2.31

Cash flow

Free cash flow fell in 5 years from 1.2B USD to 332.0M USD.

Operating cash flowCapital expenditureFree cash flow in USD
  1. Fiscal year 2016: Operating cash flow 1.7B USD · Capital expenditure 719.0M USD · Free cash flow 935.0M USD
  2. Fiscal year 2017: Operating cash flow 1.8B USD · Capital expenditure 634.0M USD · Free cash flow 1.2B USD
  3. Fiscal year 2018: Operating cash flow 2.1B USD · Capital expenditure 681.0M USD · Free cash flow 1.4B USD
  4. Fiscal year 2019: Operating cash flow 2.1B USD · Capital expenditure 696.0M USD · Free cash flow 1.4B USD
  5. Fiscal year 2020: Operating cash flow 1.9B USD · Capital expenditure 709.0M USD · Free cash flow 1.2B USD
  6. Fiscal year 2021: Operating cash flow 2.2B USD · Capital expenditure 743.0M USD · Free cash flow 1.5B USD
  7. Fiscal year 2022: Operating cash flow 1.2B USD · Capital expenditure 679.0M USD · Free cash flow 532.0M USD
  8. Fiscal year 2023: Operating cash flow 1.7B USD · Capital expenditure 692.0M USD · Free cash flow 1.0B USD
  9. Fiscal year 2024: Operating cash flow 1.0B USD · Capital expenditure 446.0M USD · Free cash flow 573.0M USD
  10. Fiscal year 2025: Operating cash flow 845.0M USD · Capital expenditure 513.0M USD · Free cash flow 332.0M USD

Share count

The share count stayed roughly the same in 5 years.

Diluted share count
  1. Fiscal year 2016: Diluted share count 551.0M
  2. Fiscal year 2017: Diluted share count 555.0M
  3. Fiscal year 2018: Diluted share count 546.0M
  4. Fiscal year 2019: Diluted share count 519.0M
  5. Fiscal year 2020: Diluted share count 517.0M
  6. Fiscal year 2021: Diluted share count 508.0M
  7. Fiscal year 2022: Diluted share count 504.0M
  8. Fiscal year 2023: Diluted share count 506.0M
  9. Fiscal year 2024: Diluted share count 510.0M
  10. Fiscal year 2025: Diluted share count 513.0M

From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.

Metrics chart

Up to three metrics stacked over the same fiscal years – so you see at a glance whether they rise together or drift apart. Point at a year to read it in every panel.

Metrics, up to 3 – to switch, deselect one first

Premium Line of a second stock for comparison

Revenue

Revenue stayed roughly the same in 5 years (11.2B USD).

BAX in USD
  1. Fiscal year 2016: BAX 10.2B USD
  2. Fiscal year 2017: BAX 10.6B USD
  3. Fiscal year 2018: BAX 11.1B USD
  4. Fiscal year 2019: BAX 11.4B USD
  5. Fiscal year 2020: BAX 11.7B USD
  6. Fiscal year 2021: BAX 12.8B USD
  7. Fiscal year 2022: BAX 15.1B USD
  8. Fiscal year 2023: BAX 14.8B USD
  9. Fiscal year 2024: BAX 10.6B USD
  10. Fiscal year 2025: BAX 11.2B USD

Net margin

The net margin fell in 5 years from 9.4% to −8.5%.

BAX Sector today 13.2% Mark in the latest year: today’s median of the Health Care sector as in the sector comparison (each latest fiscal year). We do not have earlier medians.
  1. Fiscal year 2016: BAX 48.9%
  2. Fiscal year 2017: BAX 6.8%
  3. Fiscal year 2018: BAX 14.6%
  4. Fiscal year 2019: BAX 8.8%
  5. Fiscal year 2020: BAX 9.4%
  6. Fiscal year 2021: BAX 10.0%
  7. Fiscal year 2022: BAX −16.1%
  8. Fiscal year 2023: BAX 17.9%
  9. Fiscal year 2024: BAX −6.1%
  10. Fiscal year 2025: BAX −8.5% · Sector today 13.2%

Free cash flow margin

The free cash flow margin fell in 5 years from 9.9% to 3.0%.

BAX Sector today 14.7%
  1. Fiscal year 2016: BAX 9.2%
  2. Fiscal year 2017: BAX 11.4%
  3. Fiscal year 2018: BAX 12.7%
  4. Fiscal year 2019: BAX 12.4%
  5. Fiscal year 2020: BAX 9.9%
  6. Fiscal year 2021: BAX 11.6%
  7. Fiscal year 2022: BAX 3.5%
  8. Fiscal year 2023: BAX 7.0%
  9. Fiscal year 2024: BAX 5.4%
  10. Fiscal year 2025: BAX 3.0% · Sector today 14.7%

Source: SEC filings, fiscal years up to Dec 31, 2025. The same figures as in the sections of this page, per fiscal year as first reported. Describes the reported figures – not investment advice.

How reliable is the dividend?

Dividend at a glance

The dividend per share was cut in fiscal year 2025 compared with the year before; free cash flow per share covers it 1.2x.

Years without a cut
0
cut in fiscal year 2025
Growth per year (5 yrs)
−11.4%
dividend per share, average per year
Coverage by free cash flow
1.2x
covered from 1.0x

You can see the dividend yield and shareholder yield (based on the price) with a free account. Sign up free

More depth

Calculation

  • Dividend per share: fiscal year 2020 0.96 USD → fiscal year 2025 0.52 USD = −11.4% per year
  • Free cash flow per share 0.65 USD ÷ dividend per share 0.52 USD = 1.2x

Years without a cut: in a row up to fiscal year 2025, dividend per share according to the SEC, adjusted for stock splits; only 1% less than the year before counts as a cut, also for variable dividends; a special dividend in the prior year does not. If the dividend per share falls while the total paid rises, the run ends as “unclear”. “At least” is shown only if our data ends earlier.

Shareholder yield: dividends paid plus share repurchases minus proceeds from new shares according to the cash flow statement of the last fiscal year, divided by today’s market value. Missing repurchases or new shares count as 0; without reported dividend or repurchase payments (among others for many stocks of the extended selection) there is no value. Describes the reported figures – not investment advice.

History, payout ratios and returns per year

As of fiscal year 2025 · Source: SEC filings

Valued higher or lower than usual?

Valuation against its own history

There is no comparison for the P/E: the last fiscal year ended with a loss.

With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free

Source: SEC filings and our daily candles

Dividends and share repurchases

How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.

Dividend per share
0.52 USD · Fiscal year 2025
Dividend growth per year
3 y −23.2%5 y −11.4%10 y −8.5%
Payout ratio
of earnings – of free cash flow 105%
To shareholders (5 years)
3.3B USD 19% through repurchases
Share count over 5 years
−0.8% roughly unchanged

Dividend per share

The dividend per share fell in 5 years from 0.96 USD to 0.52 USD.

Dividend per share USD per share Per share as filed with the SEC, including special dividends; obvious filing errors are hidden.
  1. Fiscal year 2016: Dividend per share 0.51 USD
  2. Fiscal year 2017: Dividend per share 0.61 USD
  3. Fiscal year 2018: Dividend per share 0.73 USD
  4. Fiscal year 2019: Dividend per share 0.85 USD
  5. Fiscal year 2020: Dividend per share 0.96 USD
  6. Fiscal year 2021: Dividend per share 1.09 USD
  7. Fiscal year 2022: Dividend per share 1.15 USD
  8. Fiscal year 2023: Dividend per share 1.16 USD
  9. Fiscal year 2024: Dividend per share 1.04 USD
  10. Fiscal year 2025: Dividend per share 0.52 USD

Payout ratios

Last reported for fiscal year 2023.

Payout ratio (earnings)Payout ratio (free cash flow)
  1. Fiscal year 2016: Payout ratio (earnings) 5.6% · Payout ratio (free cash flow) 28.7%
  2. Fiscal year 2017: Payout ratio (earnings) 47.3% · Payout ratio (free cash flow) 26.2%
  3. Fiscal year 2018: Payout ratio (earnings) 24.6% · Payout ratio (free cash flow) 26.6%
  4. Fiscal year 2019: Payout ratio (earnings) 44.0% · Payout ratio (free cash flow) 30.0%
  5. Fiscal year 2020: Payout ratio (earnings) 44.8% · Payout ratio (free cash flow) 40.8%
  6. Fiscal year 2021: Payout ratio (earnings) 42.9% · Payout ratio (free cash flow) 35.8%
  7. Fiscal year 2022: Payout ratio (earnings) not available · Payout ratio (free cash flow) 107.7%
  8. Fiscal year 2023: Payout ratio (earnings) 22.1% · Payout ratio (free cash flow) 56.7%
  9. Fiscal year 2024: Payout ratio (earnings) not available · Payout ratio (free cash flow) 103.0%
  10. Fiscal year 2025: Payout ratio (earnings) not available · Payout ratio (free cash flow) 104.8%

What goes back to shareholders

Over 5 years, 3.3B USD went back to shareholders, 19% of it through share repurchases. That is 83% of the free cash flow of those years.

Dividends paidShare repurchasesNew shares issued (including employee plans)Free cash flow in USD
  1. Fiscal year 2016: Dividends paid 268.0M USD · Share repurchases 292.0M USD · New shares issued (including employee plans) not available · Free cash flow 935.0M USD
  2. Fiscal year 2017: Dividends paid 315.0M USD · Share repurchases 564.0M USD · New shares issued (including employee plans) not available · Free cash flow 1.2B USD
  3. Fiscal year 2018: Dividends paid 376.0M USD · Share repurchases 2.5B USD · New shares issued (including employee plans) not available · Free cash flow 1.4B USD
  4. Fiscal year 2019: Dividends paid 423.0M USD · Share repurchases 1.3B USD · New shares issued (including employee plans) not available · Free cash flow 1.4B USD
  5. Fiscal year 2020: Dividends paid 473.0M USD · Share repurchases 500.0M USD · New shares issued (including employee plans) not available · Free cash flow 1.2B USD
  6. Fiscal year 2021: Dividends paid 530.0M USD · Share repurchases 600.0M USD · New shares issued (including employee plans) not available · Free cash flow 1.5B USD
  7. Fiscal year 2022: Dividends paid 573.0M USD · Share repurchases 32.0M USD · New shares issued (including employee plans) not available · Free cash flow 532.0M USD
  8. Fiscal year 2023: Dividends paid 586.0M USD · Share repurchases 0.0 USD · New shares issued (including employee plans) not available · Free cash flow 1.0B USD
  9. Fiscal year 2024: Dividends paid 590.0M USD · Share repurchases 0.0 USD · New shares issued (including employee plans) not available · Free cash flow 573.0M USD
  10. Fiscal year 2025: Dividends paid 348.0M USD · Share repurchases not available · New shares issued (including employee plans) not available · Free cash flow 332.0M USD

Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.

Valuation over time

Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users.

Sector comparison

Baxter International next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.

Sector comparison BAX, sector Health Care; last row: sector median
Symbol Revenue (FY) Growth 5 yrsGross marginOp. marginNet marginROEEquity ratioFCF marginPiotroski
AMGN Amgen 36.8B USD +7.6%67.2%24.7%21.0%89.1%9.6%22.0%7/9
MDT Medtronic 36.4B USD +3.8%65.0%17.8%13.2%9.7%53.2%14.9%7/9
GILD Gilead Sciences 29.4B USD +3.6%78.8%34.0%28.9%37.5%38.5%32.1%8/9
SYK Stryker Corporation 25.1B USD +11.8%64.0%19.5%12.9%14.5%46.9%17.1%6/9
DHR Danaher Corporation 24.6B USD +2.0%59.1%19.1%14.7%6.9%62.9%21.4%7/9
REGN Regeneron Pharmaceuticals 14.3B USD +11.0%–24.9%31.4%14.4%77.1%28.4%–
VRTX Vertex Pharmaceuticals 12.0B USD +14.1%86.2%34.8%32.9%21.2%72.8%26.6%–
BAX Baxter International this stock 11.2B USD −0.7%30.1%−2.7%−8.5%−15.6%30.6%3.0%5/9
ISRG Intuitive Surgical 10.1B USD +18.2%66.0%29.3%28.4%16.0%87.1%24.7%–
Median of the sector 27 symbols 44.3B USD +8.4%67.2%17.8%13.2%13.6%38.4%14.7%7/9

Growth 5 yrs = revenue growth per year over 5 fiscal years · Op. margin = operating margin · ROE = return on equity · FCF = free cash flow · Piotroski = F-Score (only with all 9 criteria).

Compare with the closest peer in the sector BAX next to VRTX – quality checks, metrics and depth side by side.

Figures of the last fiscal year from SEC annual reports (peers as of Nov 22, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 26 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light red: shrinking

−0.7% per year, last 5 years

Sector Health Care: median +8.5% (25 symbols)

What does this mean? Revenue: over 5 years it fell by 0.7% per year on average. The median company in the sector reached +8.5% per year.

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light gray: not computable

– per year, last 5 years

Sector Health Care: median +5.5% (20 symbols)

per share: not computable (loss in the first or last year)

What does this mean? There was a loss in the first or last year. An annual growth rate cannot be calculated meaningfully then.

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light red: Loss

−8.5% last fiscal year

Sector Health Care: median 13.9% (26 symbols)

What does this mean? Of every 100 USD in revenue there was no profit but a loss of 8.51 USD. Five years ago the margin was 9.4%.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light red: much higher

1.54 latest balance sheet

Sector Health Care: median 0.66 (19 symbols)

What does this mean? For every 1 USD of equity there is 1.54 USD of financial debt – more than twice as much as the median company in the sector (0.66). More debt amplifies good and bad years alike.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light red: despite a loss

– Dividend / earnings per share

Sector Health Care: median 56% (16 symbols)

What does this mean? The company paid a dividend in the last fiscal year although there was a loss per share; it is paid from cash flow, from reserves or with new debt.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light red: 3 loss years

7 of 10 fiscal years with a profit

What does this mean? In 7 of the last 10 fiscal years the bottom line showed a profit. 3 years ended with a loss.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
11.2B USD
Revenue vs. prior year
+5.7%
Net income (FY)
−957.0M USD
Net income vs. prior year
–
EPS (FY)
-1.87 USD
Superinvestors holding
1 of 26
Fiscal year to Dec 31, 2025 · 10-K filed Feb 12, 2026 · Balance sheet Dec 31, 2025 (filed Feb 12, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). Superinvestors: 26 tracked investors per 13F filing (as of quarter end, filed up to 45 days later); weight and change per investor in the card “Which superinvestors hold …?”.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2025Dec 31, 2025 11.2B−957.0M −8.5% −1.87 0.52 –
2024Dec 31, 2024 10.6B−649.0M −6.1% −1.27 1.04 –
2023Dec 31, 2023 14.8B2.7B 17.9% 5.25 1.16 22%
2022Dec 31, 2022 15.1B−2.4B −16.1% −4.83 1.15 –
2021Dec 31, 2021 12.8B1.3B 10.0% 2.53 1.09 43%
2020Dec 31, 2020 11.7B1.1B 9.4% 2.13 0.96 45%
2019Dec 31, 2019 11.4B1.0B 8.8% 1.93 0.85 44%
2018Dec 31, 2018 11.1B1.6B 14.6% 2.97 0.73 25%
2017Dec 31, 2017 10.6B717.0M 6.8% 1.29 0.61 47%
2016Dec 31, 2016 10.2B5.0B 48.9% 9.01 0.51 6%
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q3/26Sep 30, 2026 3.0B294.0M 9.9% 0.57 0.01 2%
Q2/26Jun 30, 2026 3.0B126.0M 4.3% 0.24 0.01 4%
Q1/26Mar 31, 2026 2.7B−15.0M −0.6% −0.03 0.01 –
Q4/25*Dec 31, 2025 3.0B−1.1B −37.9% – 0.01 –
Q3/25Sep 30, 2025 2.8B−46.0M −1.6% −0.09 0.17 –
Q2/25Jun 30, 2025 2.8B91.0M 3.2% 0.18 0.17 94%
Q1/25Mar 31, 2025 2.6B126.0M 4.8% 0.25 0.17 68%
Q4/24Dec 31, 2024 2.8B−512.0M −18.6% −1.00 0.17 –
Q3/24Sep 30, 2024 2.7B140.0M 5.2% 0.27 0.29 107%
Q2/24Jun 30, 2024 3.8B−314.0M −8.2% −0.62 0.29 –
Q1/24Mar 31, 2024 3.6B37.0M 1.0% 0.07 0.29 414%
Q4/23Dec 31, 2023 3.9B245.0M 6.3% 0.48 0.29 60%

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.

Information only – does not affect the other analysis methods, not investment advice.

Insiders

All insider transactions

In the last 12 months, insiders of this stock have not acquired or disposed of shares on the market (SEC Form 4).

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Which superinvestors hold Baxter International?

All superinvestor portfolios

1 of 26 tracked superinvestors reports a position.

Superinvestors with a position in Baxter International, weight in each portfolio
InvestorWeight in portfoliovs. previous quarterAs of
Bridgewater Associates < 0.1% +459.3% increased Q3 2026

Source: 13F filing with the US Securities and Exchange Commission, latest filing dated Nov 16, 2026. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.

Trend score –

We do not calculate a trend score for symbols in the extended universe.

Volatility and trend strength

ADX 14 (trend strength)–
Price change 60 days–

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

No recent news found. News is loaded automatically three times a day for trend stocks, symbols with a current Elliott setup and favorites.

Posts

No posts on BAX yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: BAX

Alerts with a free account: we send you an email as soon as the price moves above or below your level.

Checked after every data update: crypto hourly, stocks twice a day, precious metals every 4 hours on trading days, extended universe on weekdays after the close (daily candles) – not in real time.

↑ ↓ select · Enter open · Esc close